TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1

TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1

Viruses are able to efficiently penetrate cells, multiply, and eventually kill infected cells, release tumor antigens, and activate the immune system. Therefore, viruses are highly attractive novel agents for cancer therapy. Clinical trials with first generations of oncolytic viruses (OVs) are very...

Full description

Bibliographic Details
Main Authors: Christina Funk, Nadja Uhlig, Zsolt Ruzsics, Florentin Baur, Matthias Peindl, Sarah Nietzer, Karina Epting, Gabriele Vacun, Gudrun Dandekar, Catherine Botteron, Christian Werno, Thomas Grunwald, Susanne M. Bailer
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
oncolytic virotherapy
combined virus immunotherapy
tumor therapy
NSCLC
virus engineering
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329924000262

Internet

http://www.sciencedirect.com/science/article/pii/S2950329924000262

Similar Items